It has been shown that both PPARα pharmacological antagonism and siRNA‐mediated PPARα KD reduce the expression of c‐Myc, cyclin D1 and CDK4 in renal cell carcinoma (RCC) in vitro models 53. This evidence concerns the gene MYC and renal cell carcinoma.